Evolent Health (NYSE:EVH) Trading Up 7.9% – Should You Buy?

Posted by George Bondi on Jun 8th, 2026

Evolent Health, Inc (NYSE:EVH – Get Free Report) was up 7.9% on Monday . The company traded as high as $4.42 and last traded at $4.5550. Approximately 251,543 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 2,976,243 shares. The stock had previously closed at $4.22.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Oppenheimer cut their price objective on Evolent Health from $12.00 to $6.00 and set an “outperform” rating for the company in a research report on Monday, March 2nd. Wall Street Zen upgraded Evolent Health from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. TD Cowen restated a “buy” rating on shares of Evolent Health in a research report on Monday, March 2nd. Canaccord Genuity Group raised their price objective on Evolent Health from $4.00 to $6.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Finally, Needham & Company LLC raised their price objective on Evolent Health from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Thirteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $6.00.

Get Our Latest Stock Report on EVH

Evolent Health Trading Up 14.6%

The stock has a market cap of $543.84 million, a PE ratio of -1.01 and a beta of 0.84. The stock has a 50-day moving average price of $3.35 and a two-hundred day moving average price of $3.46. The company has a debt-to-equity ratio of 2.46, a current ratio of 1.32 and a quick ratio of 1.32.

Evolent Health (NYSE:EVH – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The technology company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. Evolent Health had a negative net margin of 26.29% and a positive return on equity of 0.36%. The firm had revenue of $496.25 million during the quarter, compared to the consensus estimate of $534.00 million. During the same quarter last year, the firm earned $0.06 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Sell-side analysts forecast that Evolent Health, Inc will post -0.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Brighton Jones LLC purchased a new stake in Evolent Health in the 4th quarter worth about $3,927,000. Eventide Asset Management LLC raised its position in Evolent Health by 54.0% in the 3rd quarter. Eventide Asset Management LLC now owns 6,292,511 shares of the technology company’s stock worth $53,246,000 after purchasing an additional 2,205,659 shares during the period. Tudor Investment Corp ET AL raised its position in Evolent Health by 174.4% in the 3rd quarter. Tudor Investment Corp ET AL now owns 689,262 shares of the technology company’s stock worth $5,831,000 after purchasing an additional 438,095 shares during the period. Rock Point Advisors LLC raised its position in Evolent Health by 21.6% in the 4th quarter. Rock Point Advisors LLC now owns 1,190,156 shares of the technology company’s stock worth $4,761,000 after purchasing an additional 211,707 shares during the period. Finally, Tejara Capital Ltd purchased a new stake in Evolent Health in the 4th quarter worth about $5,326,000.

About Evolent Health

(Get Free Report)

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.